The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child
| Autor: | Ibrahim F. Shatat, Julie Ostrye, Jenna Jones, Katherine Chessman, Brent M. Egan, Susan M. Hailpern |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Nephrology medicine.medical_specialty Diastole Blood Pressure Pharmacology Cohort Studies Heart Rate Internal medicine Heart rate Humans Medicine Child Adverse effect Antihypertensive Agents Retrospective Studies business.industry Retrospective cohort study Hydralazine Hospitalization Child Preschool Hypertension Injections Intravenous Pediatrics Perinatology and Child Health Cohort Female business medicine.drug Cohort study |
| Zdroj: | Pediatric Nephrology. 29:1403-1409 |
| ISSN: | 1432-198X 0931-041X |
| DOI: | 10.1007/s00467-014-2772-0 |
| Popis: | Intravenous (IV) hydralazine is frequently used for the treatment of elevated blood pressure (BP) in hospitalized children. Its safety and efficacy have not been examined. This is a retrospective chart review of IV hydralazine use in hospitalized children (birth to 17 years) over a 3-year period. Demographic data and data on adverse effects (AE), BP, and heart rate (HR) prior to and after each first dose were collected. The patient cohort comprised 110 children admitted to the hospital during the study period, of whom 77 received the recommended dose. Mean age of the children was 8.5 ± 5.4 years; 33 % were male, and 32.5 % were white. Pre-dose systolic and diastolic BP indexes were 1.3 and 1.2, respectively. The median reduction in systolic and diastolic BP was 8.5 and 11.5 %, respectively. Sixteen (21 %) children achieved a 25 % reduction in systolic or diastolic BP, and BP increased in 30 % of patients; 10 % of children had a BP of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|